Unable to display image

 

ParfumGigi@aol.com

Sat, 7 Oct 2006 12:03:34 EDT

Multiple 3

 

New Plastic Surgery Device Keeps Breast Implants in Place
PR Web (press release) - Ferndale,WA,USA
As cosmetic surgery patients select larger and larger breast implants the long term risk for implant displacement increases. A new ...
http://www.prweb.com/releases/2006/8/prweb431831.htm

In Implant Case, Missteps Could Hurt Dow Corning

http://query.nytimes.com/gst/fullpage.html?sec=health&res=9D00E5D91339F931A25753C1A963958260Judge Blocks Sales of Generic Plavix
Click the link below to read the full story:

http://www.miaminewtimes.com/photoGallery/index.php?c=23343&p=1&& These Could Be Yours- silicone breast implants comment on this article

Schering-Plough to Pay $435 Million
Click the link below to read the full story:

NewsTarget.com - More Headlines

Vegetables, antioxidants may lower lymphoma risk (press release)

NewsTarget.com - More Headlines

Coffee intake linked to lower diabetes risk (press release)

MSNBC-Health - More Headlines

FDA wants skin-lightening cream restrictions

NewsTarget.com - More Headlines

Chest X-ray exposure may increase likelihood of breast cancer (press release)

NewsTarget.com - More Headlines

Going where no unhydrogenated soybean oil has gone before (press release)

NewsTarget.com - More Headlines

Pomegranate juice shows stunning results in reducing heart disease risk factors, even for diabetics

NewsTarget.com - More Headlines

Psychiatric medical journal editor Nemeroff resigns after secret financial ties uncovered

CBS News-Health - More Headlines

Drug Giants Reward Friendly Lawmakers

MSNBC-Health - More Headlines

Parents want HPV shots, but cant find them

MSNBC-Health - More Headlines

Acne drug rules cause problems, doctors report

MSNBC-Health - More Headlines

NewsTarget.com - More Headlines

Weighing up new data in research (press release)

NewsTarget.com - More Headlines

Deakin University has developed a prototype tasty snack food with special health benefits. (press release)

ABC News-Health-Wire - More Headlines

A Cut Below: Americans Look Abroad for Health Care

Baltimore (MD) Sun-Health - More Headlines

Cancer patient stumbles on benefits

New York (NY) Times - Health* (Reg. Required) - More Headlines

New York (NY) Times - Health* (Reg. Required) - More Headlines

A Conversation With Mary V. Relling: Saving Lives With Tailor-Made Medication

New York (NY) Times - Health* (Reg. Required) - More Headlines

Essay: Choosing a 'God Squad,' When the Mind Has Faded

http://www.nytimes.com/2006/08/29/health/29essa.html?ex=1314504000&en=cb440cb78fcfec33&ei=5088&partner=rssnyt&emc=rsshttp://www.nytimes.com/2006/08/29/health/29conv.html?ex=1314504000&en=52aeaa42bd70fff8&ei=5088&partner=rssnyt&emc=rss

New York (NY) Times - Health* (Reg. Required) - More Headlines

Obesity Is Found to Make Ovarian Cancer Deadlier

Seattle (WA) KOMO - More Headlines

Gregoire Offers Plan B Compromise For Pharmacists

This is an offense article to me. We, have the right I; thought to make our own choice for ourselves and family members,

New York (NY) ABC7 - More Headlines

What's the best way to treat Prostate Cancer?

Fox News-Politics - More Headlines

Frist Might Not Have Met Medical License Qualifications

NewsTarget.com - More Headlines

FDA advisory panels rigged; agency rubber stamps drug approvals to please Big Pharma <<<<

NewsTarget.com - More Headlines

Pesticides Exposure Associated With Parkinson's Disease (press release)

NewsTarget.com - More Headlines

Plastics chemical bisphenol-A may promote breast cancer <<<

NewsTarget.com - More Headlines

Doctors Widely Prescribe Drugs For Uses Not Approved by the FDA (press release)

NewsTarget.com - More Headlines

Asthma is not a disease, but just a name given to various symptoms, says The Lancet

4NI (UK) - More Headlines

Cancer conference held at Queen's

Grand Rapids (MI) Press - More Headlines

Doctor faces new charges in deaths

Multiple Chemical Sensitivity (MCS): The Afflicted

People With Allergies Are More Susceptible to Chemicals

Those who are afflicted with Multiple Chemical Sensitivity (MCS) suffer from a multitude of ailments, that have very real consequences.

MCS is a worldwide illness that can affect anyone, and most who suffer from this disorder were healthy before becoming ill. Some believe that children, the elderly, and people with allergic illnesses seem to be more susceptible to chemicals than the average person. Some people can be genetically susceptible also.

More women than men are affected by this illness. It is believed that since men produce Testosterone, it often covers up the symptoms and warning signs until it is too late. Women produce Estrogen which does not cover up the symptoms.

There is also the theory that because women use more toxic products from cosmetics to household cleaners than men, they are more susceptible.

Those most likely to be associated with MCS are industrial workers, "sick building" occupants, those living in chemically contaminated communities, Gulf War veterans, and women with silicone breast implants.

Half of those with MCS also suffer with traditional (IgE) allergies, in other words, they can also be susceptible to food, mold, or dust allergies.

Causes & Triggers

Clinical Ecologists believe that repeated small exposures or one large high exposure to chemical agents over time can lead to the body losing its ability to detox. This can sensitize people and cause their immune systems to malfunction. Once the body's ability to process toxins is damaged, the person may be more susceptible to chemicals that never caused a problem before.The body's detox processes can be impaired by other means besides chemical agents. Some other causes of MCS include viruses, severe emotional or physical trauma (especially in childhood), liver damage, or metabolism disorders. Some people with MCS may have a genetic disorder of the enzyme pathways (porphyria), which may not manifest until triggered by a chemical exposure.

Multiple Chemical Sensitivity can be triggered by a multitude of chemicals. Mostly petrochemicals, they can be found in pesticides, herbicides, perfumes, fragrances, paints, wood treatments, glues, carpets, furniture, shampoo, soap, detergents, cleaners, plastics, solvents, markers, raw fuels, engine exhaust, alcohol, medications, caffeine and food additives to name a few. Pollution can also play a part in this disorder.

Symptoms

The symptoms of MCS can be similar to those of traditional allergies, such as headaches, migraines, dizziness, nausea, anaphylactic shock, breathing difficulty, rashes and other skin eruptions. Of course, there can be other symptoms such as acute abdominal pain, prolonged fatigue, insomnia, neurological signs, loss of concentration, memory loss, body aches and pains, and even progressive coordination impairment. Keep in mind this is not an all inclusive list.

Treatment

Multiple Chemical Sensitivity is difficult for physicians to diagnose because there is no single set of symptoms which fit together as a syndrome. There is also not one diagnostic test that will detect every manifestation of the disorder. Physicians must become detectives to sort out a patient's medical history and pay attention to the patient's environmental or occupational exposures in order to correctly diagnose MCS. As with allergies, avoidance is the key in treating MCS. As with its symptoms, treatment varies with the individual afflicted. It may be helpful to use an air purifying system. The American Environmental Health Foundation suggests the food you eat, and the personal care products you use may contain offensive chemicals. Be careful what you purchase and read the labels.

For additional information on Multiple Chemical Sensitivity, please refer to the collected Internet links.

Suggested Reading

MCS: The ControversyFormaldehyde ExposureFragrance Sensitivity

From Other Guides

Multiple Chemical SensitivitiesChemical SensitivityAre Scents Making You Sick?

Elsewhere on the Web

MCS for SurvivorsMCS: What Is It Really?The MCS Debate

Related Articles

Multiple Chemical Sensitivities multiple chemical sensitivity, MCS, chemicals Multiple Chemical Sensitivity (MCS): The Controversy MCS - Multiple Chemical Sensitivity - Hypersensitivity ... What Kind of Nose Do You Have?

Scientific evidence proves that:

Silicone breast implants can produce autoimmune illnesses.

Once the implants are removed, you still need to detoxify the body of silicone residuesñhereís how.

Since their introduction in 1962, silicone breast implants have been surgically emplaced in an estimated two million American women. Some women get them as part of breast reconstruction therapy following mastectomy for breast cancer, but the majority get them because they want larger breasts.

Now, 36 years later, it is alarmingly apparent that bigger, siliconized breasts can be hazardous to your health. Weíre beginning to see that the real cost of cosmetic breast enhancement may not be the $6,000 in surgical fees to implant them, but a host of autoimmune symptoms and strange illnesses that can crop up, typically within about seven years of implantation.

450,000 Siliconized Women Sue

Not everyone sees it this way of course. The subject of silicone breast implants is clouded and controversial, marked by denial, cover-up, stonewalling, suppressed research, bankruptcy, and class action lawsuits. There is also much suffering involved.

The manufacturers and most plastic surgeons strenuously insist silicone breast implants pose no health danger; most women apparently believe this because 87,704 more American women received implants in 1996. Between 1992 and 1997, the number of breast augmentation surgeries increased by 275%, according to the American Society of Plastic and Reconstructive Surgeons.

The majority were saline implants in a silicone casing; the only women still getting silicone implants are those who opt for breast reconstruction following mastectomy and agree to be part of the FDAís clinical trials on silicone implants.

Yet thousands of women who have had their implants for one or two decades now are seeking medical help for mysterious symptoms which resemble arthritis, fibromyalgia, scleroderma, connective tissue disorders, and/or immune dysfunction and seem to be associated with their implants. In 1992, the FDA declared a moratorium on sales of silicone breast implants, citing the lack of clinical studies proving their safety. However, the FDA did not say silicone implants were unsafe, hedging, as usual, on the side of manufacturers and against the public, calling lamely for more studies. Yet as early as 1954 an in-house study by Dow Corning, a prime implant manufacturer, found that the silica in silicone has quite a high order of toxicity,according to recently released documentation of that previously suppressed study. In 1956, silicone fluid injected into laboratory dogs migrated to all the major organs; and in 1961, the year the first implants were released, Dowís own internal medical research department reported that silicone leaking from implants is equivalent in toxic effect to direct injections of silicone into the body.

Prior to implants, that had been the preferred method of breast enhancement. But in the 1940s, Japan, for one, banned this procedure for its immunologically toxic effects, which included poisoning, infections, and the early development of cancer. Even so, it remained legal in the U.S. until the 1960s. In 1984, setting a precedent for all women with implants and silicone-associated illnesses, a woman named Maria Stern won $1.5 million in damages for autoimmune symptoms produced by her implants. Litigation momentum has been building ever since.

By 1995, an estimated 450,000 American women had qualified to be part of a gigantic $4.25 billion class action suit against the silicone implant manufacturers. Many of the injured women fell through the litigation cracks in 1995 when Dow Corning, one of the principal defendants, declared bankruptcy, thereby taking itself conveniently off the fiscal hook. But now that Dow Corning has agreed to a smaller global settlement ($3.2 billion allocated, announced in July 1998), perhaps some injured women will finally receive at least some recompense.

As medical authorities and scientific expertscontinually downplay the risks of implants and assert that no association between implants and symptoms has been proven, the case for silicone implant toxicity is growing, fueled in large measure by the fact-finding efforts of the Plaintiffís Steering Committee (PSC) for the National Breast Implant Litigation, consolidated in Birmingham, Alabama. This national committee, appointed by U.S. District Court Judge Sam Pointer, is comprised of 17 attorneys from around the country.

The nationally consolidated cases are known as the Silicone Gel Breast Implant Product Liability, Multi-District Litigation Action No. 926.Part of the Committeeís job, according to Karen E. Read, chief staff attorney for the PSC Office of Liaison Counsel, is to gather and organize evidence suitable for use in any and all court actions against the silicone implant makers. In legal terms, itís called discovery.î

We are nearly finished with the discovery process now and a slew of cases, sitting dormant for years, are about to go back to the courts for litigation,says Read. Litigants can potentially use any or all of the evidence we developed nationally in their jurisdictional trials.That is, if they havenít been intimidated by the manufacturerís lawyers and dropped out, Read adds. Siliconized women are under a lot of pressure not to press their claims.

First, the strongest cases, the ones most potentially damaging to the silicone makersñsuch as clearly proven deaths or cancerñoften get settled out of court to avoid adverse publicity, Read explains.

Second, women, in the process of giving their depositions, are sometimes subjected to ruthless grilling and character assassinationby the defense lawyers, in a manner similar to the way rape victims are blamed for attracting the crime, Read claims. Theyíre asked about secret, private, embarassing things, such as their sexual history. Women end up settling for almost nothing just to have it be over.î

Third, about 50,000 women have already opted to pursue their own case independently in court rather than accept the minimal sums now being offeredñin some cases, a mere 5% of the original proposed settlement, says Read.

Whatever the outcome of the individual court cases and the class action lawsuit, the evidence for the toxicity of silicone implants is increasing daily, despite the firewall of denial and derision erected by mainstream medicine and the FDA. Here is a précis of the facts, as gathered from scientific studies:


1. Silicone is a biologically active and toxic substance.

The original statement by the Dow Chemical Company in the 1940s, repeated hundreds of times since, that silicone is biologically inert and nontoxic, was based on a single one-week study of rats and guineas pigs. (In 1943, Dow Chemical Company and Corning Glassworks formed Dow Corning Corporation to market silicone and silicone implants.) The basic gel implant fillerñDC 360 silicone fluidñwas once considered worth following upfor development by Dow Corning scientists as a potent insecticide, one of the few known substances capable of killing cockroaches. Dow Corning researchers also studied silicone as a possible better chemical warfare and riot control agent,according to a 1969 internal memorandum obtained by the PSC. The silicone gel is not a single substance but a fluid comprised of numerous different versions of silicone, such that it is better termed a chemical soup.î
Research collected by the PSC shows that silicone has marked effects on the adrenal glands and liver, induces chronic inflammation, and degrades into smaller molecules, including silica. Silicone fed to rabbits produced widespread toxic effects including kidney and spleen damage within four months. (Stanford Medical Bulletin, 10:1 [1952], 23-26.) That silicone is toxic in both animals and man is well proven,stated John S. Sergent, M.D., and colleagues in Textbook of Rheumatology (W.B. Saunders Company, 1993).
Silicone degrades into silica, usually at the surface of the gel implant, then fragments and subdivides into millions of microdroplets capable of migrating throughout the body (PSC Records No. 1352, 7017: these are documents produced by Dow Corning in national litigation). Silica in the body is a toxic, carcinogenic substance, damaging the immune system, killing cells, and producing silicosis. Silicone and its contaminants which bleed through its surrounding implant envelope into neighboring tissue have the potential for significant toxicity in the implant recipient.(Seminars in Arthritis and Rheumatology 24:1 Suppl 1 [August 1994], 11-17.) According to research gathered by attorney Richard Alexander, of the Alexander Law Firm in San Jose, California, Dow Chemical and Dow Corning have been aware of the toxic effects of silicone and silica since the 1950s, based on their own studies, but never published the data. They knew these substances were bioreactive, immunogenic, toxic, and inflammatory when introduced into the human body,states Alexander. (Update on Breast Implants,January 1998, website: http://consumerlawpage.com.) Researchers at the University of California at Los Angeles School of Medicine concluded in 1995: From a pathophysiological perspective, silicones should be expected to be bioactive materials and the physico-chemical and immunological data at the experimental level are compelling.(Journal of Biomaterials Science, Polymer Edition 7:2 [1995], 101-13.

2. Implants will likely rupture and leak within ten years of placement.

In 1995, then FDA Commissioner David A. Kessler, M.D., stated that the rupture rate of silicone implants ranges between 5% and 51% and that unfortunately we do not know with any confidence where within that range the real rupture rate lies.î
When 51 implants were removed, one to 17 years after implantation, 27 were found to have ruptured, 7 were leaking, and only 17 were in good condition; all implants older than ten years were leaking or ruptured. (Plastic Reconstructive Surgery 91:5 [April 1993], 828-834.)
Based on an examination of 350 silicone implants, doctors found that 63% of those implants in place for 12 years or more were not intact. (Plastic and Reconstructive Surgery 99:6 [1997], 1597-1601.)
According to Lu-Jean Feng, M.D., of Mt. Sinai Medical Center in Cleveland, Ohio, in evidence presented to the PSC, 11% of implants which have been in the body less than seven years rupture, but of those in the body more than seven years, 61% rupture.
Deformities such as holes or cracks were found in 40% of 1,717 breast implants after six years of use and in 95% after 12 years of use. (Canadian Journal of Plastic Surgeons [Spring 1997].)
When breast implants from 300 patients were examined, 71% had either rupture or silicone bleed, or both, and 63% of 592 implants, when removed, were found to have ruptures. This led researchers to conclude: We have found and predict that most implants have lost or will lose the integrity of the silicone shell between eight and 14 years, leaving free silicone [in and out of the capsule] in the breast.(Annals of Plastic Surgery 34:1 [January 1995], 1-6.)
Based on an examination of 217 silicone implants removed during a four-year period, physicians concluded that, either from leakage or rupture, 40% failed within six years of implantation, and 95% within 12 years. (Canadian Journal of Plastic Surgery 4:1 [1996], 55-58.)
Using magnetic resonance spectroscopy, researchers found that among 39 women with implants, 20 (51%) had ruptured implants and 27 (69%) had evidence of silicone in their livers. (Radiology 201:3 [December 1996], 777-783.)
Complications of implants requiring further surgery are likely within five years, based on a study of 749 women with silicone implants. During a median span of 7.8 years after implantation, 27% of the women underwent 450 implant-related surgeries; 79% of these surgeries were needed to address a complication, most frequently among which were capsular contraction (tightening of scar tissue around the implant) and rupture. (New England Journal of Medicine 336:10 [March 6, 1997], 677-682.)
French researchers found that the well-described leakage occurring through the silicone envelope allows the silicone gel to diffuse to multiple anatomic areas in the body,producing a cellular response that includes the formation of a capsule around the implant. (Revue de Medecine Interne 18:12 [1997], 955-966.)

3. Silicone migrates from the rupture site throughout the body.

As early as 1956, Dow Chemical researchers knew that liquid silicone, when injected into the body, migrates to all the major organs, including the spleen, heart, lung, and brain. (PSC Record No. 0006.)
Studies by both Dow Corning and Dow Chemical in 1970 confirmed that silicone, after injection, migrates to the bone marrow of animals and changes brain weight. They also showed that silicone particles migrate from a human finger joint into the lymph nodes. (PSC Record No. 0018, 7038.)
Researchers at Baylor College of Medicine in Texas found that silicone is widely distributed throughout the body of mice after a single injection, migrating to ten different organs from the brain to the uterus and persisting in these organs over time. (American Journal of Pathology 152:3 [March 1998], 645-649.)
Researchers at the Medical College of Wisconsin in Milwaukee found that following silicone implant rupture, silicone gel migrated into the arm of a woman, where it produced nerve pain, dysfunction, and fibrosis. (Plastic Reconstructive Surgery 89:5 [May 1992], 949-952.)
Physicians at Massachusetts General Hospital in Charlestown, using magnetic resonance imaging, found that a significant amount of free siliconehad migrated from an implant (not noticeably ruptured) into the liver and spleen of a woman. (Magnetic Resonance Medicine 36:3 [September 1996], 498-501. Researchers also found that silicone in the liver could be detected in the first three to four years after a woman received her implant. (Magnetic Resonance Medicine 33:1[January 1995], 8-17.)
Of 39 women with silicone implants, 27 (69%) showed signs of silicone in their livers, and of the 20 whose implants had ruptured, silicone was detected in the livers of 17 (85%). In other words, whether the implants rupture or not, silicone leaks and migrates to the liver. (Radiology 201 [1996], 777-783; PSC Record No. 0050.)
In 1989, studies by Dow Corning showed that silicone, given orally to rats, increased liver size and weight by up to 45% and suggested the enlargement might be interpreted as a carcinogenic response. (PSC Record No. 0482.)

4. Silicone produces abnormalities in immune system functioning.

Silicone elicits antibody responses and immunological abnormalities,according to a study of 40 women who had received implants more than ten years earlier. Among these women, 60% had an elevated ratio of helper T cells to suppressor T cells; 20% had a blockage in particular functions of T cells and natural killer cells. (Toxicology Industrial Health 8:6 [November/December 1992], 415-429.)
Scientists at the University of California at Davis reported that evidence suggests that the degradation products of silicone inactivate CD8+ suppressor T cells (key immune cells) and thereby lead to an inflammatory state in the body. (Food and Chemical Toxicology 32:11 [November 1994], 1089-1100.)
The activity of natural killer cells is significantly suppressedin at least 50% of women with silicone implants observed in a study; this puts the women at a higher risk of developing cancer. The same effect was demonstrated in animals; it was reversed upon removal of the silicone. (Toxicology and Industrial Health 10:3 [May/June 1994], 149-154.)
High levels of anti-nuclear antibodies (ANAs), immune markers associated with lupus erythematosus, were observed in ten of 11 women with implants reporting autoimmune symptoms. (Lancet 340:8831 [November 28, 1992], 1304-1307.)
When 500 women with silicone implants were examined, 30% tested positive for ANA levels; those women also had rheumatic symptoms. The results strongly suggested immune activation in women with silicone implants.(Current Topics in Microbiological Immunology 210 [1996], 277-282.)
Based on a study of 3,380 breast implant recipients, scientists state there is a sixfold increased likelihood that testing these women will show elevated ANAs; the longer the implant has been in place, the greater the likelihood. (Current Topics in Microbiological Immunology 210 [1996], 337-353.)
In a study of 111 women (with and without implants), those with implants had a statistically significant elevationof anti-silicone antibodies (immune cells focused against silicone as a foreign substance in the body); the highest levels were observed in women with noticeable implant rupture or leakage. (FASEB 7:13 [October 1993], 1265-1268.)
Researchers at the University of Wisconsin at Madison School of Medicine reported that autoantibodies of unclear significance may be found in 5% to 30% of women with silicone breast implants.(Archives of Internal Medicine 153:23 [December 1993], 2638-2644.)
Researchers at Monash University in Clayton, Victoria, in Australia, found that women with silicone implants (70 were studied) have elevated levels of autoantibodies to collagen, in a manner highly similar to women with lupus and rheumatoid arthritis. (Current Topics in Microbiological Immunology 210 [1996], 307-316.)
Among 310 symptomatic women with silicone implants, there were elevated levels of novel autoreactive antibodies to silicone associated antigens(a specific type of heightened immune response) compared to healthy women without implants. (Current Topics in Microbiological Immunology 210 [1996], 327-336.)
Scientists at the Technical University of Munich in Germany examined 239 breast implant recipients and found the following immunological abnormalities: levels of complement C3 were elevated in 42% of the women; complement C4 was elevated in 21%; and antithyroglobulin (an antibody that attacks a substance in the thyroid gland) was higher in 28%. (Annals of Plastic Surgery 36:5 [May 1996], 512-518.)
When silicone leaks from implants, immune cells form granulomas (microscopic lumps) around the droplets; the granulomas are capable of severely disrupting the immune system. Silicone plays the role of an adjuvant,providing constant nonspecific stimulation of the immune system.(Journal of Investigative Surgery 9:1 [January/February 1996], 1-12.)

5. Silicone produces a classifiable new disease marked by autoimmune symptoms.

Among physicians willing to credit silicone with toxicological and immunological effects, a variety of names for silicone-induced disease have been proposed: siliconosis, undifferentiated or atypical connective tissue disease, silicone related disease, silicone reactive disorder, silicone disease syndrome, and silicone implant disease (SID).
Typical symptoms associated with silicone include cognitive dysfunction, short-term memory loss, Sjögrenís syndrome (dryness in glands, such as the mouth, kidneys, eyes, and lungs), scleroderma, rheumatoid arthritis, dermatomyositis, severe joint and muscle pain, incapacitating fatigue, swollen lymph glands, skin problems, peripheral numbness, multiple allergies, headaches, hair loss, sunlight sensitivity, central nervous system disorders (similar to multiple sclerosis), and others.
Among 176 breast implant patients examined by doctors at the Hospital for Joint Diseases, Orthopaedic Institute, in New York City, the most frequently reported symptoms were chronic fatigue (77%), cognitive dysfunction (65%), severe joint pain (56%), dry mouth (53%), dry eye (50%), hair loss (40%), and difficulty in swallowing (35%). (Seminars in Arthritis and Rheumatology 24:1 Suppl 1 [August 1994], 29-37.)
A study of 50 women with implants revealed that 89% complained of fatigue, 75% of generalized stiffness, 71% of poor sleep, and 78% of joint pain. Positive ANAs were found in 38% of these patients. (Seminars in Arthritis and Rheumatology 24:1 Suppl 1 [August 1994], 44-53.)
A study of 56 women with silicone implants and scleroderma (skin thickening which damages tissues) revealed that scleroderma symptoms developed an average of nine years after implantation. Of these, 77% also had Raynaudís phenomenon (extreme skin pallor and coldness in hands and feet), 53% had swallowing difficulties, 47% had lung problems, and 83% had antinuclear antibodies. (Current Topics in Microbiological Immunology 210 [1996], 283-90.)
Doctors at the CompreCare Clinic in Houston, Texas, found that 26 women developed a systemic disease with central nervous system involvement (resembling multiple sclerosis) an average of 5.7 years after receiving silicone implants. (Southern Medical Journal 89:2 [February 1996], 179-88.)
Doctors at the Louisiana State University Medical Center at New Orleans examined 300 women (average age, 44) with silicone implants and musculoskeletal complaints. The symptoms developed an average of 6.8 years after receiving the implants; 83% had symptoms highly suggestive of an underlying connective tissue disorder;and 54% met the criteria for a fibromyalgia (chronic muscle pain) diagnosis. (Clinical Rheumatology 14:6 [November 1995], 667-672.)
According to Douglas R. Shanklin, M.D., and David L. Smalley, M.D., both professors of pathology at the University of Tennessee at Memphis, there is little if any difference between the effects of direct injection [of silicone] and the effects of gel-filled devices [implants].î
In either case, the human body reacts to the presence of this alien substanceî by forming granulomas which then produce a chronic inflammation. Direct injection of silicone into the breast for enlargement was outlawed because it produced serious, toxic effects in women; it is illogical, state Drs. Shanklin and Smalley, that this practice is still permitted via ruptured leaking implants. (Science and Medicine 3:5 [September/October 1996], 22-31.)

6. Silicone-associated symptoms go away when implants are removed.

Doctors at the University of Alabama at Birmingham observed that 103 of 142 women attributed a variety of symptoms to their implants and that 50% of these women reported improvement in their health problems when the implants were removed. (Annals of Plastic Surgery 34:1 [January 1995], 1-6.)
Of 33 women who underwent implant removal (average age 44), 24 experienced significant improvement in numerous silicone-associated symptoms within 22 months. (Seminars in Arthritis and Rheumatology 24:1 Suppl 1 [August 1994], 22-28.)
Among 300 women with implants and musculoskeletal complaints, 70% who underwent implant removal reported improvement in their systemic symptomatology. (Clinical Rheumatology 14:6 [November 1995], 667-672.)
Dermatologists at the Medical University of South Carolina at Charleston report that when a woman, 46, with scleroderma had her implants removed, the scleroderma gradually resolved.(Archives of Dermatology 126:9 [September 1990], 1198-1202.)
Doctors at the University of California, Davis School of Medicine report that for a woman with debilitating multisystem sarcoidosis (multiorgan granulomas), her clinical condition dramatically improved,after her silicone implants were removed. (International Archives of Allergy and Immunology 105:4 [December 1994], 404-407.)
Canadian researchers polled 100 women for health changes they experienced after having their silicone implants removed (mean age 41) after having had the implants for a mean of 12 years. After an average of 2.7 years, 45% of 75 women in this group (those who had lost nipple sensitivity) believed, in retrospect, their implants had caused permanent health problems and 43% were suing the implant manufacturers.
Those women who had no previous signs of autoimmune symptoms responded most favorably to explantationas 80% reported major improvementin their symptoms and 93% said they had a significantly improved psychological well-being.(Annals of Plastic Surgery 39:1 [1997], 9-19.)
Surely there is enough evidence to support the case that silicone breast implants pose a serious potential health threat, if not for every woman, at least for many. Isnít it therefore prudent to side with cautionñhaving the implants removed and residual silicone detoxified from the bodyñif the health ramifications of a procedure are that uncertain?

http://www.lightparty.com/Health/Health.htmlhttp://www.lightparty.com/Health/Health.html

Back to Top

Back to Health Directory

Home

http://www.lightparty.com/Health/SiliconePoison.html

BBC News - Northern Ireland (UK) - More Headlines

Cancer treatment being discussed

In Breast Implants Scandal, Where was Dow Corning’s Concern for Women?

In the annals of business ethics, the fall from grace of Dow Corning Corporation was particularly precipitous. Here was one of America’s 100 most profitable industrial companies. Its high-level Business Conduct Committee, which dated back to the 1970s, was considered an industry model: It conducted annually some 25 face-to-face audits worldwide with employee groups. More than ninety percent of Dow Corning employees considered the company "highly ethical," according to a 1988 company survey, an exceptionally high rating.

That was all before the silicone breast implants scandal.
Even though the health hazards associated with the silicone implants came to light gradually, over years, the defining moment for John E. Swanson was a June 1991 story in Business Week magazine (dated June 10, 1991). This was the first article that alleged that Dow Corning concealed documents about the product’s safety. "It was the first time the company’s ethics were questioned in a public way. To me, it was a shock," recalls Swanson, then manager of internal communications and the sole permanent member of the company’s Business Conduct Committee. After 26 years with the company, "I thought I knew where all the skeletons were."
The article alleged that silicone breast implants could deteriorate and leak, wreaking havoc upon a woman’s immune system. The company had long maintained that the implants it manufactured through Dow Corning Wright, its subsidiary company, would last a woman’s lifetime. At the time of the article, approximately 1.5 million to 2 million women had had silicone breast implants. It was the third largest form of cosmetic surgery after nose and liposuction operations. Nevertheless, Business Week charged that the industry had known for a decade of animal studies that linked implants to cancer and other illnesses.
On June 4, 1991, Swanson sent to the company’s corporate Comptroller, who was chairman of the Business Conduct Committee, a note via electronic mail about the Business Week article, which he said clearly raises ethical issues and "casts a cloud over the company" that was hurting its "hard-earned reputation" as an organization committed to integrity. Swanson said that "it was time to re-examine our position."
He reasoned that if there is a growing body of anecdotal evidence of health problems (even in the absence of the usual animal studies, epidemiological studies, etc.), should a responsible manufacturer stay in the market? Could it really countenance continuing to supply 130,000 women a year with implants? It wasn’t as if the business was making the company much money, after all. The implant business accounted for less than 1 percent of the Midland, Michigan-based company’s sales.
Swanson discussed the case for suspending sale and manufacture with the company’s Business Conduct Committee, which in addition to Swanson and the Comptroller, included Dow Corning’s Director of Sales and Marketing and its Vice President and General Manager of the company’s largest industrial business, among others. (The Committee did not include the three or four top decision makers in the company. Nonetheless, Swanson says the committee had influence within the company. "It had easy access to the CEO and to anyone in the company. It was a well-regarded committee of senior managers.")

A decision to keep manufacturing

The issue came to a head at a Corporate Board of Directors meeting on June 10, 1991. Prior to that meeting, Swanson spoke with the executive who had been assigned responsibility in the implant controversy. Swanson suggested a tactic to pre-empt discussion: A fictional press release for use at the meeting. It read in part:
"Dow Corning Wright will suspend the manufacture and sale of breast implants until research on certain bio-safety issues has been concluded. Since entering the market in 1963, Dow Corning has continuously studied the health and safety effects of these devices . . . and believes them to be safe. But it also recognizes that questions about the safety of silicone implants exist. We are placing a high priority on finding scientifically sound answers to these questions." The board met. The breast implant controversy was discussed. Unfortunately, the board decided to stay in the business, recalls Swanson.
Why did it not react? The company had become "hypersensitive about its legal position," suggests Swanson. The company had paid $1.5 million in punitive damages in a major 1984 lawsuit in which a federal district judge had found the company’s implants inherently defective. The judge had noted that the company’s own studies "cast considerable doubt on the safety of the product," the results of which were not disclosed to patients. The judge called the company’s actions "highly reprehensible."
Following the Business Week article and the board meeting, the company apparently believed that to suspend production would be to admit the product was dangerous and would invite further legal action.

A damaged reputation

This was an "interesting perspective," comments Swanson. When the company has one to two million women with silicone breast implants and has lost a lawsuit on the issue of fraud and the concealment of information, one might think that would "serve as a wake-up call." Perhaps the company should simply have said, "To hell with the legal defense" and looked first at the health of its women users.

The result of Dow Corning’s decision not to suspend manufacture was to exacerbate a situation that eventually was to result in approximately 12,000 lawsuits by early 1994 and a proposed $4.25 billion global settlement. (The mass settlement included other silicone implant manufacturers as well as suppliers and doctors.)
The company’s reputation suffered grievously. By March 1992, the common view of the company in the public mind was that its devices were not safe, that it had covered up evidence about their safety, that it was insensitive, and that its actions amounted to a 30-year medical experiment on women who were uninformed as to the risks.
The company’s CEO was demoted as a result of the affair. In March 1992, the company commenced getting out of the silicone breast implant business. Dow Chemical Chairman Frank Popoff (Dow Corning is a joint venture between Dow Chemical Co. and Corning, Inc.) declared in April 1992 that CEO Lawrence Reed was "not emotionally equipped" to deal with the crisis. Dow Corning lost more than $287 million in 1993.

How could it happen?

How could a well-regarded company reach such a pass? There were several reasons, in Swanson’s view. He speaks of an "insulated organizational syndrome." The company had only two shareholders, after all, Dow Chemical and Corning, Inc., and as a result it had operated independent of the scrutiny to which most large public companies are subject. There was an "attitude of invincibility" within the company. In the area of silicone technology the company was regarded as a world leader and some of its managers may have felt they could do no wrong in this area.
There was management’s inability to gauge the public’s perceptions, too. Dow Corning’s position was and is that all the scientific evidence was still not in regarding the safety of silicone breast implants. Technically, this is correct. But meanwhile the company was "losing the battle in public opinion." It was seen as a callous corporation, indifferent to the plight of its product’s end users.
There was a lack of crisis-management leadership too. If one criterion for selection of a new CEO back in 1984 had been how well the chief executive understood the company’s various constituencies, including its ultimate customers and government regulators, then Lawrence Reed probably would not have made the final cut, in Swanson’s view. "Reed was inexperienced" in many of these stakeholder matters, including crisis management.

Where was the Business Conduct Committee?

Still, for so-called business ethics practitioners, a further question has to be: What happened to Dow Corning’s vaunted Business Conduct Committee? Could it not influence the outcome in a case that clearly had ethical implications? And if not, does that not call into question the efficacy of not only this committee but of business conduct committees in general? Are such committees, in fact, nothing more than fig leaves on the secular corporate body?
"In a very broad sense, if you have a wonderful process, and good communications, and also have few major problems, then the program will look very good, and that was the case for a long time," says Swanson.
For a company with sales in the $2 billion range, Dow Corning had a relatively small employee base: less than 9,000 employees. This enabled the company to "put together a business ethics program that had the potential of touching all the company’s people in the world at some time."
Swanson estimates that from the 1970s, Dow Corning conducted some 500 ethics audits with employee groups, half in locations outside the U.S. and as far afield as Europe and South America. It was a "great way to educate employees" in business conduct issues. Many sessions were conducted by senior officers. Swanson conducted hundreds himself.
His final judgment is harsh, however: "I’d categorize the process as good time ethics." When it came to the real test, Dow Corning failed.

A failure of leadership

"What Dow Corning needed was a leader with a sixth sense that told him: ‘This company has values that insist that we stand up for the women who have used our products.’" Until they knew for sure the health repercussions, they should have taken the devices off the market.
Moreover, if the company had stood up and admitted its mistakes and said, "We have to make them right," it is Swanson’s view that "the media would have lacked the incentive to keep digging unrelentingly into the company’s past." The company’s stonewalling in the affair only encouraged further media scrutiny.
"The finest and most elaborate ethics programs are no more effective than the company’s leadership permits them to be."
Nor does Swanson think that the company only needed to do something in the early 1990s when the controversy reached public light. Dow Corning could have "stepped up" to the issue decades earlier when it was known that women who were users of the product weren’t getting all the information needed to make informed judgments. Why did the company think that it was sufficient to provide information only to the plastic surgeons who inserted the devices? What assurance did the company have that women were getting information from the plastic surgeons?

Employee surveys

That the whole affair took a toll on employee morale is not surprising. As mentioned, the company conducted an employee survey in 1988 before the breast implant controversy arose that found that over 90 percent of its domestic employees considered Dow Corning a "highly ethical company." In 1992, while the controversy was in full swing, the company did another survey. Not surprisingly, its ethics rating dropped. It did not drop precipitously, however. Seventy-seven percent of employees still said Dow Corning was a "highly ethical company." This seems noteworthy. Many companies that have avoided major scandals would probably be pleased if as many as 50 percent of employees viewed them as "highly ethical."
The fact that many employees stood by the company might serve as some consolation in the whole tale. "Over a period of time, from 1976 on, pride in ethical conduct was very important to the company," recalls Swanson. Dow Corning is fortunate to have an employee base "that has hung in with them through all the bad publicity." Evidence introduced in implant trials and many of Dow Corning’s long-suppressed safety studies when released had "not put the company in a good light." The fact that employees remained "amazingly loyal" might be attributed in part to the attention paid to business ethics through the years. That, at least, is one way of salvaging something of value.

A new CEO

Keith R. McKennon was brought in from Dow Chemical Company to take over running the company after Reed was demoted in 1992. He was probably the "best guy" for the task, in Swanson’s view. A veteran of Dow’s Chemical’s Agent Orange controversy, McKennon was skilled in dealing with the media. The company’s new "theme" became its concern for women with implants. McKennon gave more than 100 interviews in his first month on the job, including an hour on the Larry King show.
"He became visible and displayed more sensitivity." McKennon announced a $10 million research program to find answers to some of the health and scientific questions that had been raised in the affair. McKennon admitted that Dow Corning had made errors, the first time the company had publicly confessed to this.
In early 1993, Swanson spoke with McKennon’s successor, Richard Hazleton, about the Business Conduct Committee. "What we arrived at was a new process for changing the role of the Business Conduct Committee from a leadership body to a facilitating role." They discussed ways to integrate the committee’s former responsibilities into those of Dow Corning’s line management.
The Business Conduct Committee now represents all geographic areas, not just the U.S., as was the case earlier. The new structures should move the process toward a "day to day activity rather than an event-linked" process. Not ‘inherently bad’ Swanson insists that the company did and does have an ethical culture. "It is not an inherently bad company with evil intentions." On the contrary, Dow Corning has "good people," and if one looks at its 50-year history, "it is a very good one, with only one black mark." During that 40 to 50 year period, however, the company operated in an unusual environment, shielded by its two shareholders and led by managers who were chemists or chemical engineers and weren’t called upon to concern themselves with crisis management. According to Swanson they were a "bright group of linear problem solvers," highly analytic managers whose biggest challenge was traditionally deciding which of the company’s promising technologies to commercialize.

When the crisis surfaced, Dow Corning was "shocked and didn’t know how to handle it."

Out of the loop

The controversy resulted in Swanson’s leaving the company. In September 1991, "I approached top management. I told them that I had an ethical conflict of interest with the company’s breast implant position." He also related that at some time after leaving the company he wanted to do further work in business ethics and "could not espouse the Dow Corning role" in this affair.
After making this decision, "I thought there was a reasonable chance that the company might try to move me out, but they didn’t do that. So I removed myself from communications activities relating to implants and concentrated more on business conduct activities."
He let his staff know his views. They were not to give him any information on breast implants. Essentially he took himself out of the loop where breast implants were concerned and remained so for the next two years. He remained on the Business Conduct Committee.
Swanson recognized that taking issue with the company on such a major matter was obviously "not a career builder." He left the company in August 1993 after things had become increasingly uncomfortable. "It became clear to me that the company was committed to one position and I believed in a very different one."
He moved from Michigan to Indiana where he now conducts his own consulting business, Applied Business Ethics. He may eventually write a book on the breast implant controversy.
Did he feel personally betrayed? After all, Swanson spent 26 years of his life with the company, significant parts of it spent traveling to places like Brazil to propound the business ethics theme. Arguably, all that work was over-shadowed by the breast implant controversy.
"If it had happened in a major part of the business, I would have been very demoralized by the failure." But it is one of the ironies of the affair that it occurred in the smallest of Dow Corning’s businesses, the health care area, a business that accounted for a minor percentage of the company’s sales.
"I can see how the business conduct process missed it." Breast implants simply didn’t receive the management attention that other parts of the business—industrial sealants, say—received.
But that does not change the fact that it wasn’t until 1993 that Dow Corning finally changed its patient implant book to say that it had "no definitive data on the life expectancy of the implants," and that they may not last beyond 10 years. Until that time the company had insisted that the implants would last a woman’s lifetime.
Asks Swanson: How many women would have elected to have silicone breast implants if they had known that they might have to have a major operation to replace them every seven to ten years?
"The ethics process worked while the company had no problems," says Swanson. "But when the company’s feet were put to the fire, the process failed."

printed in 1994

Dow, Still has no ethics; and have become bigger liars as these long years have passed!

Gigi-Karen Lawrence

Pittsburgh (PA) KDKA - More Headlines

Report: Doctors' 275M Study Questioned

NewsTarget.com - More Headlines

Interview: Dr. Christine Horner discusses choices women can make to prevent breast cancer #1 is don't have breast Implants to prevent several types of cancer!!

Grand Rapids (MI) Press - More Headlines

Doctor accused of million-dollar fraud

Breast augmentation: Breast implants reshape self-image
MayoClinic.com - USA
Understand the surgical process, including what it means to have breast implants, possible complications and what you can expect from the surgery. ...
See all stories on this topic
http://www.mayoclinic.com/health/breast-implants/WO00052

http://www.mayoclinic.com/health/contact-us/contactus

Use the form below to send a message to our Customer Service staff. You’ll receive a reply via e-mail. Please note the following:

Please indicate the subject of your message (required)
I need help finding health information or tools on your site.
I need help with registration, login or technical issues.
I want to provide feedback about your site.
Other
Read this entire slop the, Mayo Clinic has put out again. Dow, paid the; Mayo Clinic to lie on their study once!

http://www.newstarget.com/z020029.html

Judge Tosses Merck Win, Orders New Trial
Click the link below to read the full story:
http://www.forbes.com/feeds/ap/2006/08/17/ap2957886.html?partner=alerts
http://www.newstarget.com/z020029.html

Inner City Press - Bronx,NY,USA
A manufacturer and distributor of Agent Orange, Dow Chemical, was celebrated at the UN less than a month ago, in a luncheon addressed by Deputy Secretary ...
http://www.innercitypress.com/ungc082206.html

 


Go BackHomeGo Forward